Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis

Turina, M.; Sieper, Joachim; Yeremenko, Nataliya; Conrad, Kristina; Haibel, Hildrun; Rudwaleit, Martín; Baeten, Dominique; Poddubnyy, Denis

doi:10.1136/annrheumdis-2014-205506

Cited by 73 publications

(60 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Turina et al measured serum calprotectin levels of 76 patients with axial spondyloarthritis (axSpA). They found higher levels of serum calprotectin in axSpA patients when compared with the control group and showed that this could be an independent risk factor for radiographic progression [13]. Davida et al tested fecal calprotectin levels of 17 AS patients and found 57% positivity.…”

Section: Discussionmentioning

confidence: 99%

Fecal calprotectin is associated with disease activity in patients with ankylosing spondylitis

Duran

Kobak

Şen

et al. 2016

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

Calprotectin is one of the major antimicrobial S100 leucocyte proteins. Serum calprotectin levels are associated with certain inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel disease. The aim of this study was to investigate serum and fecal calprotectin levels in patients with ankylosing spondylitis (AS) and show their potential relations to the clinical findings of the disease. Fifty-one patients fulfilling the New York criteria of AS and 43 healthy age-and gender-matched volunteers were included in the study. Physical and locomotor system examinations were performed and history data were obtained for all patients. Disease activity parameters were assessed together with anthropometric parameters. Routine laboratory examinations and genetic testing (HLA-B27) were performed. Serum calprotectin levels and fecal calprotectin levels were measured by an enzyme-linked immunosorbent assay. The mean age of the patients was 41.5 years, the mean duration of the disease was 8.6 years, and the delay in diagnosis was 4.2 years. Serum calprotectin levels were similar in both AS patients and in the control group (p=0.233). Serum calprotectin level was correlated with Bath AS disease activity index (BASDAI) and Bath AS functional index (BASFI) (p=0.001, p=0.002, respectively). A higher level of fecal calprotectin was detected in AS patients when compared with the control group. A statistically significant correlation between fecal calprotectin level and BASDAI, BASFI, C-reactive protein and Erythrocyte sedimentation rate were detected (p=0.002, p=0.005, p=0.001, p=0.002, respectively). The results indicated that fecal calprotectin levels were associated with AS disease findings and activity parameters. Calprotectin is a vital disease activity biomarker for AS and may have an important role in the pathogenesis of the disease. Multi-centered prospective studies are needed in order to provide further insight.

show abstract

Section: Discussionmentioning

confidence: 99%

Fecal calprotectin is associated with disease activity in patients with ankylosing spondylitis

Duran

Kobak

Şen

et al. 2016

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

show abstract

“…94 CLP decreases rapidly upon effective treatment with TNF-a-inhibitors and secukinumab in both axial and peripheral SpA and it has been suggested as a useful biomarker for disease monitoring, where it performs even better than high-sensitivity CRP. 91,95 Baseline CLP was also found to be an independent predictor of radiographic spinal progression in axial SpA in a cohort of German patients. 95 CLP concentration >0.5 mg/mL was associated with worsening of the modified Stoke Ankylosing Spondylitis Spine Score and the development or progression of syndesmophytes at the two year follow-up.…”

mentioning

confidence: 99%

“…91,95 Baseline CLP was also found to be an independent predictor of radiographic spinal progression in axial SpA in a cohort of German patients. 95 CLP concentration >0.5 mg/mL was associated with worsening of the modified Stoke Ankylosing Spondylitis Spine Score and the development or progression of syndesmophytes at the two year follow-up. 95 …”

mentioning

confidence: 99%

“…95 CLP concentration >0.5 mg/mL was associated with worsening of the modified Stoke Ankylosing Spondylitis Spine Score and the development or progression of syndesmophytes at the two year follow-up. 95 …”

mentioning

confidence: 99%

“…Indeed, almost no correlation was found between CLP and Ankylosing Spondylitis Disease Activity Score, 82 Bath AS disease activity index, or Bath AS functional index. 89,91,92,[94][95][96] Notably, CLP is secreted not only in the joints, but also in other inflamed tissues such as the gastrointestinal mucosa. Up to 50% of patients with SpA have subclinical bowel inflammation, which is associated with increased serum levels of CLP.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Calprotectin in rheumatic diseases

Ometto

Friso

Astorri

et al. 2016

Exp Biol Med (Maywood)

136

105

View full text Add to dashboard Cite

Calprotectin is an acute-phase protein produced by monocytes and neutrophils in the circulation and inflamed tissues. Calprotectin seems to be more sensitive than CRP, being able to detect minimal residual inflammation and is a candidate biomarker in inflammatory diseases. High serum levels are associated with some severe manifestations of rheumatic diseases, such as glomerulonephritis and lung fibrosis. Calprotectin levels in other fluids, such as saliva and synovial fluid, might be helpful in the diagnosis of rheumatic diseases. Of interest is also the potential role of calprotectin as a target of treatment. AbstractCalprotectin is a heterodimer formed by two proteins, S100A8 and S100A9, which are mainly produced by activated monocytes and neutrophils in the circulation and in inflamed tissues. The implication of calprotectin in the inflammatory process has already been demonstrated, but its role in the pathogenesis, diagnosis, and monitoring of rheumatic diseases has gained great attention in recent years. Calprotectin, being stable at room temperature, is a candidate biomarker for the follow-up of disease activity in many autoimmune disorders, where it can predict response to treatment or disease relapse. There is evidence that a number of immunomodulators, including TNF-a inhibitors, may reduce calprotectin expression. S100A8 and S100A9 have a potential role as a target of treatment in murine models of autoimmune disorders, since the direct or indirect blockade of these proteins results in amelioration of the disease process. In this review, we will go over the biologic functions of calprotectin which might be involved in the etiology of rheumatic disorders. We will also report evidence of its potential use as a disease biomarker.

show abstract

Serum Adipokine Levels in Patients With Ankylosing Spondylitis and Their Relationship to Clinical Parameters and Radiographic Spinal Progression

Syrbe

Callhoff

Conrad

et al. 2015

Arthritis & Rheumatology

Self Cite

View full text Add to dashboard Cite

Objective. Adipokines have metabolic and inflammatory functions but can also affect bone metabolism. The purpose of this study was to determine the relationship between serum levels of adiponectin, resistin, and visfatin and markers of inflammation, disease activity, and radiographic spinal progression in patients with ankylosing spondylitis (AS).Methods. Levels of adiponectin, resistin, and visfatin in the serum of 86 AS patients and 25 healthy controls were measured by enzyme-linked immunosorbent assay at baseline. Radiographic spinal progression was determined by the scoring of radiographs of the spine obtained at baseline and after 2 years.Results. Mean (؎SD) baseline levels of resistin and visfatin were significantly higher in AS patients than in healthy controls (11.6 ؎ 10.6 ng/ml versus 6.6 ؎ 3.2 ng/ml [P ‫؍‬ 0.01] for resistin, and 20.9 ؎ 48.3 ng/ml versus 3.4 ؎ 2.6 ng/ml [P ‫؍‬ 0.001] for visfatin). Adipokine serum levels did not correlate with disease activity or functional indices. Only resistin serum levels correlated with markers of inflammation. Baseline levels of visfatin, but not resistin or adiponectin, were significantly higher in patients with worsening of the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) by >2 units after 2 years (n ‫؍‬ 19) as compared to patients without mSASSS worsening (37.7 ؎ 57.8 ng/ml versus 16.1 ؎ 44.6 ng/ml; P ‫؍‬ 0.029) and in patients with syndesmophyte formation/ progression (n ‫؍‬ 22) as compared to patients without such progression (37.1 ؎ 55.3 ng/ml versus 15.3 ؎ 44.8 ng/ml; P ‫؍‬ 0.023). Visfatin levels of >8 ng/ml at baseline were predictive of subsequent radiographic spinal progression (adjusted odds ratio 3.6 for mSASSS progression and 5.4 for syndesmophyte formation/progression).Conclusion. Serum levels of resistin and visfatin are elevated in AS patients. Elevated visfatin levels at baseline are predictive of subsequent progression of radiographic damage in AS patients.

show abstract

Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis

Cited by 73 publications

References 8 publications

Fecal calprotectin is associated with disease activity in patients with ankylosing spondylitis

Fecal calprotectin is associated with disease activity in patients with ankylosing spondylitis

Calprotectin in rheumatic diseases

Serum Adipokine Levels in Patients With Ankylosing Spondylitis and Their Relationship to Clinical Parameters and Radiographic Spinal Progression

Contact Info

Product

Resources

About